Selected research
Industry Research
Tumor Models Industry Research Report 2026
Market perspective
The global Tumor Models market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Tumor Models market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tumor Models market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tumor Models market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tumor Models include Labcorp, IITRI, InSphero, Biomodels, Reaction Biology, Oncodesign Services, Creative Biolabs, Abnova and Invivocue, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Tumor Models market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tumor Models.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Models Market by Company
Labcorp
IITRI
InSphero
Biomodels
Reaction Biology
Oncodesign Services
Creative Biolabs
Abnova
Invivocue
Inotiv
Charles River
WuXi Biology
Tumor Models Segment by Type
Cell Line-derived Xenograft (CDX) Tumor Models
Patient-derived Xenograft (PDX) Tumor Models
Syngeneic Tumor Models
Others
Tumor Models Segment by Application
Clinical Trials
Academic Research
Others
Tumor Models Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Models market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Models and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Models.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tumor Models companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Line-derived Xenograft (CDX) Tumor Models
- Patient-derived Xenograft (PDX) Tumor Models
- Syngeneic Tumor Models
- Others
Applications
- Clinical Trials
- Academic Research
- Others
Companies covered
- Labcorp
- IITRI
- InSphero
- Biomodels
- Reaction Biology
- Oncodesign Services
- Creative Biolabs
- Abnova
- Invivocue
- Inotiv
- Charles River
- WuXi Biology
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Tumor Models by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cell Line-derived Xenograft (CDX) Tumor Models
- 2.2.3 Patient-derived Xenograft (PDX) Tumor Models
- 2.2.4 Syngeneic Tumor Models
- 2.2.5 Others
- 2.3 Tumor Models by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinical Trials
- 2.3.3 Academic Research
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Tumor Models Breakdown Data by Type
- 3.1 Global Tumor Models Historic Market Size by Type (2021-2026)
- 3.2 Global Tumor Models Forecasted Market Size by Type (2027-2032)
4 Tumor Models Breakdown Data by Application
- 4.1 Global Tumor Models Historic Market Size by Application (2021-2026)
- 4.2 Global Tumor Models Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Tumor Models Market Perspective (2021-2032)
- 5.2 Global Tumor Models Growth Trends by Region
- 5.2.1 Global Tumor Models Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Tumor Models Historic Market Size by Region (2021-2026)
- 5.2.3 Tumor Models Forecasted Market Size by Region (2027-2032)
- 5.3 Tumor Models Market Dynamics
- 5.3.1 Tumor Models Industry Trends
- 5.3.2 Tumor Models Market Drivers
- 5.3.3 Tumor Models Market Challenges
- 5.3.4 Tumor Models Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Tumor Models Players by Revenue
- 6.1.1 Global Top Tumor Models Players by Revenue (2021-2026)
- 6.1.2 Global Tumor Models Revenue Market Share by Players (2021-2026)
- 6.2 Global Tumor Models Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Tumor Models Head Office and Area Served
- 6.4 Global Tumor Models Players, Product Type & Application
- 6.5 Global Tumor Models Manufacturers Established Date
- 6.6 Global Tumor Models Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Tumor Models Market Size (2021-2032)
- 7.2 North America Tumor Models Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Tumor Models Market Size by Country (2021-2026)
- 7.4 North America Tumor Models Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Tumor Models Market Size (2021-2032)
- 8.2 Europe Tumor Models Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Tumor Models Market Size by Country (2021-2026)
- 8.4 Europe Tumor Models Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Tumor Models Market Size (2021-2032)
- 9.2 Asia-Pacific Tumor Models Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Tumor Models Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Tumor Models Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Tumor Models Market Size (2021-2032)
- 10.2 South America Tumor Models Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Tumor Models Market Size by Country (2021-2026)
- 10.4 South America Tumor Models Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Tumor Models Market Size (2021-2032)
- 11.2 Middle East & Africa Tumor Models Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Tumor Models Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Tumor Models Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Labcorp
- 12.1.1 Labcorp Company Information
- 12.1.2 Labcorp Business Overview
- 12.1.3 Labcorp Revenue in Tumor Models Business (2021-2026)
- 12.1.4 Labcorp Tumor Models Product Portfolio
- 12.1.5 Labcorp Recent Developments
- 12.2 IITRI
- 12.2.1 IITRI Company Information
- 12.2.2 IITRI Business Overview
- 12.2.3 IITRI Revenue in Tumor Models Business (2021-2026)
- 12.2.4 IITRI Tumor Models Product Portfolio
- 12.2.5 IITRI Recent Developments
- 12.3 InSphero
- 12.3.1 InSphero Company Information
- 12.3.2 InSphero Business Overview
- 12.3.3 InSphero Revenue in Tumor Models Business (2021-2026)
- 12.3.4 InSphero Tumor Models Product Portfolio
- 12.3.5 InSphero Recent Developments
- 12.4 Biomodels
- 12.4.1 Biomodels Company Information
- 12.4.2 Biomodels Business Overview
- 12.4.3 Biomodels Revenue in Tumor Models Business (2021-2026)
- 12.4.4 Biomodels Tumor Models Product Portfolio
- 12.4.5 Biomodels Recent Developments
- 12.5 Reaction Biology
- 12.5.1 Reaction Biology Company Information
- 12.5.2 Reaction Biology Business Overview
- 12.5.3 Reaction Biology Revenue in Tumor Models Business (2021-2026)
- 12.5.4 Reaction Biology Tumor Models Product Portfolio
- 12.5.5 Reaction Biology Recent Developments
- 12.6 Oncodesign Services
- 12.6.1 Oncodesign Services Company Information
- 12.6.2 Oncodesign Services Business Overview
- 12.6.3 Oncodesign Services Revenue in Tumor Models Business (2021-2026)
- 12.6.4 Oncodesign Services Tumor Models Product Portfolio
- 12.6.5 Oncodesign Services Recent Developments
- 12.7 Creative Biolabs
- 12.7.1 Creative Biolabs Company Information
- 12.7.2 Creative Biolabs Business Overview
- 12.7.3 Creative Biolabs Revenue in Tumor Models Business (2021-2026)
- 12.7.4 Creative Biolabs Tumor Models Product Portfolio
- 12.7.5 Creative Biolabs Recent Developments
- 12.8 Abnova
- 12.8.1 Abnova Company Information
- 12.8.2 Abnova Business Overview
- 12.8.3 Abnova Revenue in Tumor Models Business (2021-2026)
- 12.8.4 Abnova Tumor Models Product Portfolio
- 12.8.5 Abnova Recent Developments
- 12.9 Invivocue
- 12.9.1 Invivocue Company Information
- 12.9.2 Invivocue Business Overview
- 12.9.3 Invivocue Revenue in Tumor Models Business (2021-2026)
- 12.9.4 Invivocue Tumor Models Product Portfolio
- 12.9.5 Invivocue Recent Developments
- 12.10 Inotiv
- 12.10.1 Inotiv Company Information
- 12.10.2 Inotiv Business Overview
- 12.10.3 Inotiv Revenue in Tumor Models Business (2021-2026)
- 12.10.4 Inotiv Tumor Models Product Portfolio
- 12.10.5 Inotiv Recent Developments
- 12.11 Charles River
- 12.11.1 Charles River Company Information
- 12.11.2 Charles River Business Overview
- 12.11.3 Charles River Revenue in Tumor Models Business (2021-2026)
- 12.11.4 Charles River Tumor Models Product Portfolio
- 12.11.5 Charles River Recent Developments
- 12.12 WuXi Biology
- 12.12.1 WuXi Biology Company Information
- 12.12.2 WuXi Biology Business Overview
- 12.12.3 WuXi Biology Revenue in Tumor Models Business (2021-2026)
- 12.12.4 WuXi Biology Tumor Models Product Portfolio
- 12.12.5 WuXi Biology Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst